Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Published

on

global-functional-dyspepsia-drug-market-to-reach-a-valuation-of-us$-164-billion-by-2034,-future-market-insights,-inc.-projection

US functional dyspepsia drug market to grow at 5.1% CAGR till 2034. Rising GI disorders, aging population drive demand. Korea is set to be the top performing market, exhibiting a CAGR of 7.0% through 2034.
NEWARK, Del., May 1, 2024 /PRNewswire/ — The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development. Joint research efforts accelerate the discovery of novel therapeutic targets and the translation of scientific findings into clinical applications.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-19518
Growing acceptance and utilization of complementary and alternative medicine approaches, such as herbal remedies, acupuncture, and mind body therapies, create opportunities for the development of natural or herbal based pharmacological treatments.
Investments in healthcare infrastructure, including the establishment of specialized gastrointestinal clinics and endoscopy centers, improve access to diagnostic services and specialist care for patients with functional dyspepsia. The infrastructure development supports the diagnosis and management of the condition, fuelling the market growth.
Harmonization of regulatory standards and the establishment of expedited approval pathways for gastrointestinal drugs across different regions streamline the drug development process.
It also facilitates market entry, encouraging investment in functional dyspepsia drug development. Research into the role of gut microbiota in gastrointestinal health has led to interest in developing drugs that modulate the microbiome to alleviate functional dyspepsia symptoms.
Probiotics, prebiotics, and fecal microbiota transplantation are areas of exploration, offering potential for novel treatment options. Advancements in regenerative medicine, including tissue engineering and stem cell therapies, offer potential for tissue repair and regeneration in gastrointestinal disorders like functional dyspepsia.
Regenerative approaches may provide long term therapeutic benefits and address underlying pathologies. Emphasis on patient reported outcomes and patient preferences in drug development processes promotes the development of drugs that align with patient needs and preferences.
Patient centric approaches enhance treatment satisfaction, adherence, and overall healthcare outcomes. The digitization of healthcare records and the widespread adoption of electronic health record systems facilitate data sharing and real time monitoring of patient outcomes.
Key Takeaways from the Market Study:
Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.From 2019 to 2023, the market demand expanded at a CAGR of 6.5%.The market in Korea to expand at a CAGR of 7.0% through 2034.By indication, the functional dyspepsia segment to account for a CAGR of 4.6% through 2034.The market in China will expand at a CAGR of 5.5% through 2034.In terms of channel, the over the counter segment to account for a CAGR of 4.4% through 2034.”EHR integration with decision support tools enhances clinical decision making and improves the management of functional dyspepsia,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
Request Customization of Report: https://www.futuremarketinsights.com/customization-available/rep-gb-19518
Competitive Landscape:
The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.
Company Portfolio:
Salix Pharmaceuticals, Inc. specializes in developing and commercializing gastrointestinal therapeutics for conditions such as functional dyspepsia. The company offers a range of products targeting different aspects of gastrointestinal health, including medications for symptom relief and disease management.Abbott Laboratories is a diversified healthcare company with a presence in various therapeutic areas, including gastroenterology. Abbott offers medications such as proton pump inhibitors, antacids, and digestive enzyme supplements.Report Scope:
Attribute
Details
Estimated Market Size in 2024
US$ 10.3 billion
Projected Market Valuation in 2034
US$ 16.4 billion
Value-based CAGR 2024 to 2034
4.8 %
Forecast Period
2024 to 2034
Historical Data Available for
2019 to 2023
Market Analysis
Value in US$ billion
Key Regions Covered

North AmericaLatin AmericaWestern EuropeEastern EuropeSouth Asia and PacificEast AsiaThe Middle East & AfricaKey Market Segments Covered

IndicationDrug TypeMedicationChannelDistribution ChannelRegionKey Countries Profiled

The United StatesCanadaBrazilMexicoGermanyFranceFranceSpainItalyRussiaPolandCzech RepublicRomaniaIndiaBangladeshAustraliaNew ZealandChinaJapanSouth KoreaGCC countriesSouth AfricaIsraelKey Companies Profiled

Takeda Pharmaceutical Company LimitedAstraZeneca plcSalix Pharmaceuticals Inc.Abbott LaboratoriesPfizer Inc.Sanofi SAProcter & GambleHaleon plcANI Pharmaceuticals, Inc.Dr. Reddy’s Laboratories Ltd. 
Get a Purchase on the Report: https://www.futuremarketinsights.com/checkout/19518
Segmentation Analysis of the Functional Dyspepsia Drug Market:
By Indication:
Functional DyspepsiaOrganic DyspepsiaBy Drug Type:
Proton Pump InhibitorsH-2-Receptor AntagonistsAntacidsAntibioticsProkineticsAntidepressantsBy Medication:
Branded MedicineGeneric MedicineBy Channel:
Over the CounterPrescriptionBy Distribution Channel:
Retail PharmaciesHospital PharmaciesOnline PharmaciesBy Region:
North AmericaLatin AmericaWestern EuropeEastern EuropeSouth Asia and PacificEast AsiaThe Middle East and AfricaAuthor By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:
General Anesthesia Drugs Market Size: The global general anesthesia drugs market size is estimated at US$ 4,978.1 million in 2023. Projections indicate a steady growth with a steady CAGR of 3.3% anticipated between 2023 and 2033. This trajectory is expected to lead the market to exceed US$ 6,898.4 million by 2033.
Psychotropic Drugs Market Share: The global Psychotropic Drugs Market size is US$ 21,269.4 million in 2023 and is expected to reach US$ 28,876.2 million by 2033. The global market is estimated to expand at a CAGR of 3.1% during the forecast period.
Lip Filler Market Growth: The lip filler market size is eyeing a valuation of US$ 738.2 million by 2034. The expansion is estimated at a 3.6% CAGR until 2034. In 2024, the valuation stands at US$ 518.3 million.
Nuclear Imaging Equipment Market Trends: The sales of nuclear imaging equipment are estimated to evolve at a CAGR of 5.4% between 2024 and 2034. The nuclear imaging equipment market size is expected to expand from US$ 3 billion in 2024 to US$ 5.1 billion through 2034.
Aesthetic Medical Device Market Outlook: The aesthetic medical device market is valued at US$ 13.73 billion in 2024 and is projected to reach US$ 18.82 billion by 2034, exhibiting a CAGR of 3.20% over the forecast period.
Infusion Pump Market Overview: The infusion pump market is expected to expand at a CAGR of 7.2% over the projected period. The market value is projected to increase from US$ 104.7 million in 2024 to US$ 209.8 million by 2034.
CTNG Testing Market Development: The CTNG testing market is projected to be worth US$ 1.8 billion in 2024. The market is anticipated to reach US$ 3.9 billion by 2034. The market is further expected to surge at a CAGR of 8.0% during the forecast period 2024 to 2034.
GLP-1 Receptor Agonist Market Strategy: The GLP-1 receptor agonist market is projected to be valued at US$ 23,854.53 million in 2024 and is expected to rise to US$ 72,127.79 million by 2034. It is expected to grow at a CAGR of 11.7% during the market forecast period.
Disposable Spinal Instrument Market Demand: The disposable spinal instrument market is expected to develop at a CAGR of 7.2% during the projected period. The market value is projected to increase from US$ 70.4 million in 2024 to US$ 141.1 million by 2034.
Ultrasound Conductivity Gel Market Forecast: The ultrasound conductivity gel market is estimated to be worth US$ 321.7 million in 2024. The market is expected to grow at a CAGR of 6.7% from 2024 to 2034. By the end of the forecast period, the market value is predicted to hit US$ 615.3 million.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us: Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: [email protected]: https://www.futuremarketinsights.comLinkedIn | Twitter | Blogs | YouTube
Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/global-functional-dyspepsia-drug-market-to-reach-a-valuation-of-us-16-4-billion-by-2034–future-market-insights-inc-projection-302132027.html

Continue Reading

Artificial Intelligence

Reliance Cyber and Google Cloud Security unite to transform cybersecurity for UK businesses

Published

on

reliance-cyber-and-google-cloud-security-unite-to-transform-cybersecurity-for-uk-businesses

LONDON, May 28, 2024 /PRNewswire/ — Leading Managed Security Service Provider (MSSP), Reliance Cyber has been selected as one of only four MSSPs to partner with Google Cloud Security (GCS). This collaboration is set to make cybersecurity more effective and less complicated for businesses throughout the UK and Ireland.

Why this matters:In today’s complex security environment, businesses face a multitude of challenges, including escalating cyberattacks, an overwhelming number of security alerts, rising cybersecurity costs, and a critical shortage of skilled professionals. The partnership between Reliance Cyber and Google Cloud Security provides organisations with improved security postures through insightful, data-driven analytics, which underpin Reliance Cyber’s XDR service. For businesses facing diverse economic, social, and technological changes—such as the ongoing impacts of COVID-19, the transition to hybrid and remote work, rapid technological advancements like AI, and budget pressures from the cost of living crisis—this partnership represents a significant step forward. It enhances cybersecurity without the usual challenges of high costs, complexity, or the need for specialised staff. It’s about making world-class security simple and available to a wider audience.
What’s changing:
Support for growth: The partnership will expand the reach of state-of-the-art security services to more businesses, helping to protect organisations without the stress of financial and operational barriersEnhanced visibility, lower costs: Leveraging Google’s SOAR capabilities and Chronicle’s powerful telemetry, Reliance Cyber’s tailored ingestion approach means organisations can achieve enhanced visibility across their digital environments at a reduced cost. This approach enables proactive prevention and detection of threats, ensuring better security with less expenditure.Key benefits of the strategic partnership include:
AI and automation: Automation is at the core of Reliance Cyber’s offering. Every alert is enriched with threat intel from leading vendors, automatically correlated, and grouped into cases, reducing mean time to detect (MTTD) and mean time to respond (MTTR). Google’s additions enhance this with lower data ingestion costs, superior threat intelligence, curated detections, and advanced anomaly detection using machine learningSimplified security operations to support staff: Integration of Google Cloud’s SOAR capabilities simplifies the security management landscape, allowing CISOs to focus on strategic planning rather than daily operational hurdlesScalable security for business growth: The partnership supports business expansion strategies by providing scalable security solutions that grow with the company, crucial for organisations driving technological advancementData-driven insights for better decision-making: Boards will gain unparalleled visibility into their digital environments, fostering smarter, faster decision-making to preemptively address potential security threats.Rob Walton, Chief Revenue Officer at Reliance Cyber, on the transformative impact: “We’re thrilled to partner with Google Cloud Security. This partnership aligns perfectly with our mission to deliver comprehensive, advanced security services to the market, making top-level security accessible and manageable for businesses of all sizes. Ultimately, it’s about creating predictability and peace of mind in an area that can often cause businesses and their boards sleepless nights, particularly due to concerns about attacks and the financial constraints that dictate risk appetites.”
Do you want more coverage, at less cost, with zero compromises? 
Enquire about a proof of concept. Visit: https://eu1.hubs.ly/H09bKtG0.
About Reliance Cyber
Since our founding in 2003, Reliance Cyber has established itself as a leading Managed Security Service Provider (MSSP). By combining deep cybersecurity expertise with a true partnership ethos, we enable organisations to concentrate on their core business.
Logo – https://mma.prnewswire.com/media/2418301/Reliance_Cyber.jpgLogo – https://mma.prnewswire.com/media/2418300/Google_Cloud.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/reliance-cyber-and-google-cloud-security-unite-to-transform-cybersecurity-for-uk-businesses-302156568.html

Continue Reading

Artificial Intelligence

Eficode acquires Jodocus and reinforces Atlassian Cloud skills and Atlassian partnership in Germany

Published

on

eficode-acquires-jodocus-and-reinforces-atlassian-cloud-skills-and-atlassian-partnership-in-germany

HELSINKI, May 28, 2024 /PRNewswire/ — Eficode has acquired Jodocus, the first cloud-native Atlassian Platinum partner in Germany. This acquisition further reinforces Eficode’s role as an Atlassian partner in Germany and expands its skills and services in Atlassian Cloud.

“Atlassian is moving to the Cloud, and the related know-how is essential to speed up this transition. Jodocus was originally the first Atlassian partner in Germany to focus fully on the Cloud. Their broad expertise in Atlassian tools and cloud migrations helps our customers in their journey to the cloud and complements our mission to build the future of software development,” says Ilari Nurmi, CEO of Eficode. “We welcome Jodocus’ employees and customers to Eficode.”
Founded in 2019, Jodocus is an Atlassian Platinum Solution Partner with extensive expertise in Atlassian Cloud. In addition to focusing on the Cloud, the Jodocus team offers support on business processes, Application Lifecycle Management, and DevOps. Their customer base is in Germany, with well-known names such as Otto Group and Fricke. Jodocus has 45 employees, and its revenue in 2023 was 11,5 million euros. “Together, Eficode and Jodocus will form a more significant entity and have even more international customers, which opens possibilities for deepening and broadening our relationship with our customers,” says Werner Krandick, CEO of Jodocus.
Eficode has enabled countless businesses with DevOps and digital transformation to adopt new technologies and practices to create software better. Its full spectrum of digital services can now be extended also to Jodocus’ customers. Eficode ROOT provides software development tools as a managed service in a Software-as-a-Service manner. In turn, with Total Support, we manage the tools and offer support, coaching, and mentoring for Atlassian solutions as a subscription.
In recent years, Eficode has grown strongly both organically and through acquisitions. Eficode’s compound annual growth (CAGR) during the previous four fiscal years has been 70%.
Media contactsIlari Nurmi, Chief Executive Officer, Eficode. [email protected], +358 40 577 5084 Lauri Palokangas, Chief Marketing Officer, Eficode. [email protected], +358 50 486 4918 
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eficode-oy/r/eficode-acquires-jodocus-and-reinforces-atlassian-cloud-skills-and-atlassian-partnership-in-germany,c3988509
The following files are available for download:
https://news.cision.com/eficode-oy/i/eficode-acquires-jodocus,c3304183
eficode acquires jodocus
 

View original content:https://www.prnewswire.co.uk/news-releases/eficode-acquires-jodocus-and-reinforces-atlassian-cloud-skills-and-atlassian-partnership-in-germany-302156539.html

Continue Reading

Artificial Intelligence

New first of its kind UK legal-tech recruitment platform aims to put an end to overseas worker scams

Published

on

new-first-of-its-kind-uk-legal-tech-recruitment-platform-aims-to-put-an-end-to-overseas-worker-scams

Unique UK-based legal technology platform, Immpact, helps unite the global talent market to fulfil UK skills shortages across healthcare, construction, engineering, life sciences and hospitality Immpact directly connects employers, recruiters and regulated legal experts with pre-qualified global talent – and aims to help eradicate profiteering job scammersREADING, England, May 28, 2024 /PRNewswire/ — A unique new legal-tech recruitment platform has launched in the UK to help put an end to overseas worker scams and directly connect UK employers and recruiters with pre-qualified overseas global talent. Immpact will help fulfil acute skills shortages across sectors including healthcare, construction, engineering, life sciences and hospitality, while ensuring full legal Home Office compliance.

The launch of Immpact follows over two years of advanced legal-tech development. Using the immigration law expertise of Founder and Managing Director, Jonathan Beech, and his team of specialists, the platform will help unite a previously disconnected global talent market with under-resourced UK employers and transform global workplace migration. Immpact has also been developed through discussions with hundreds of employers, industry bodies and overseas talent.
With job scams – from fake jobs to illegal fees for sponsor licences – ongoing, particularly in the social and healthcare sector, Immpact will ensure only pre-qualified talent, employers and recruitment firms are placed on its platform following stringent multi-layer checks. This will ensure that all jobs and talent are qualified and genuine along with thoroughly regulated employers and recruiters, to provide a global marketplace for talent.
Jonathan Beech, Founder and Managing Director of Immpact, said: “Through my existing business running Migrate UK, I’m acutely aware of the issues that UK employers and recruiters are having in trying to fulfil talent shortages across sectors such as care, healthcare and life sciences. I also regularly hear terrible stories of genuine overseas job hunters being ripped off in their home countries or the UK by job scammers, often running to thousands of pounds.
“I knew there had to be a better way to match pre-qualified overseas talent with genuine work opportunities and responsible UK employers – effectively a ‘talent’ match-making site which is designed to eradicate scammers to provide a global, trusted marketplace for talent.”
Following the latest government immigration rule changes, overseas recruitment costs are continuing to rise for businesses struggling with talent shortages. From 4 April 2024, the minimum salary for entering the new skilled visa worker route for the first time increased by 48%, from £26,200 to £38,700 a year. There are different rates for those already holding a skilled worker certificate of sponsorship prior to this date and discounts are available for key shortage roles on the Immigration Salary List (ISL).
Immpact will benefit employers and recruiters by saving them time and money. Working with recruitment experts to analyse existing overseas recruitment workflows, Immpact has calculated that it will save 50% of the time involved in managing overseas recruitment, helping to cut down the time-consuming filtering of applications traditionally needed.
For employers traditionally looking to recruit overseas applicants, previous data from industry recruitment software specialists show that 30% of overseas applications are rejected as they do not have the right to work, while 64% are rejected due to CVs being unclear or requirements not being met. This leaves just 6% of applications remaining, which results in about 2% then being interviewed. Immpact will automatically present only suitable pre-qualified applications to employers or recruiters, eradicating wasted time on unsuitable or unqualified applicants.
Beech continues: “Following thousands of hours of development and utilising the latest advanced technology which can adapt to evolving Home Office requirements and procedures, we’re proud to launch Immpact. Our unique new platform takes care of the entire process – from pre-qualifying processes, searching and shortlisting, down to arranging interviews, successful appointments, onboarding, the provision of regular content and guidance, and access to regulated immigration legal professionals.
“Our new technology will transform global migration for both UK organisations and businesses struggling to recruit and global talent looking to work in the UK. Immpact has been thoroughly tested at every stage and is both user-friendly and, crucially, compliant, so qualified overseas applicants and UK employers and recruiters can be confident that only genuine UK jobs and overseas applicants match and proceed. Quite simply, we want Immpact to simplify the whole migration process by putting the right talent in the right place at the right time, and for UK employers to fulfil critical talent shortages which will help them not only survive, but thrive.”
The platform has a free trial or low-cost subscriber options for search-matching and more for employers and recruiters. For talent, the platform has zero costs for creating a profile, using the pre-qualifying tools or searching for opportunities. For further information visit www.immpact.ai.
Photo – https://mma.prnewswire.com/media/2421643/Founder_and_Managing_Director_Immpact.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/new-first-of-its-kind-uk-legal-tech-recruitment-platform-aims-to-put-an-end-to-overseas-worker-scams-302155226.html

Continue Reading

Trending